Regulatory History Empowers enforcement record spans nearly a decade across both its 503A and 503B operations: 2017 FDA Warning Letter issued after a 2015 inspection found that Empower produced drug products without valid prescriptions for individually identified patients, and that sterile drug products were prepared under insanitary conditions that put patients at risk 2021 FDA Warning Letter issued to the 503B outsourcing facility after a 2020 inspection found that drug products failed to meet the conditions of Section 503B of the FDCA 2024 FDA Form 483 documented fill weight discrepancies in semaglutide vials, inadequate quality control sampling procedures, and deficiencies in aseptic processing areas April 2025 FDA Warning Letter cited drug products intended or expected to be sterile that were prepared, packed, or held under insanitary conditions
What Is the Weight Management Program
This unique mechanism could make allulose especially valuable for metabolic health applications
doi: 10.1111/resp.12312 41 AustinPC
Tell patients to look out for increasing redness, warmth, or drainage from the injection sites and contact their healthcare provider immediately if they notice these signs
Probiotics with a specific strain such as L.fermentum ME-3 are considered a good supplement as it contains both glutathione peroxidase and glutathione reductase that helps to increase glutathione production
